Cleocin Vaginal Ovules are branded clindamycin phosphate vaginal suppositories labeled at 100 mg per ovule. Their solid vaginal dosage form differs from Cleocin 2% vaginal cream and from clindamycin oral capsules, although the antibiotic name overlaps. This page concentrates on the brand and package identity of the ovules.
A patient searching “Cleocin vaginal” can encounter cream and suppository listings side by side. The product cannot be identified accurately by the brand family alone: route, solid ovule presentation and prescribed directions are essential. Consult the general ovules guide for formulation details beyond this brand.
The practical aim is to recognize the 100 mg branded suppository on a U.S. prescription, understand major label cautions and ask useful pharmacy questions. Published drug labeling is not proof of immediate local availability, and it should not be used to substitute the ovule for another vaginal product.
Cleocin Vaginal Ovules contain clindamycin phosphate in a suppository form intended for intravaginal delivery. The number 100 mg refers to the clindamycin amount associated with the individual ovule; it is not a percentage of cream or the amount in a topical antibiotic tube.
The brand name should be read together with “vaginal ovules” or “vaginal suppositories.” The broader vaginal clindamycin hub explains cream and gel alternatives but does not replace checking the exact prescribed product.
| Identity element | Cleocin Vaginal Ovules | What not to confuse it with |
|---|---|---|
| Dosage form | Solid vaginal ovule | 2% cream tube or gel |
| Strength | 100 mg per ovule | 2% concentration |
| Route | Intravaginal | Oral capsules |
| Base caution | Oil-based; latex/rubber 72-hour warning | Different brand intervals |
| Product record | Prescription brand | Inventory confirmation |
| Pharmacy check | Exact ovule package and directions | General “clindamycin” listing |
Cleocin cream and ovules are both vaginal clindamycin products, yet their formulation, packaging and directions are different. A 100 mg suppository cannot be judged equivalent to 2% cream by comparing the number alone; one refers to milligrams in a solid dosage unit, the other to a concentration.
For a structured comparison, use vaginal cream vs ovules. The prescribing clinician determines suitability; pharmacy substitution must follow product and legal requirements.
The ovule base is designed for vaginal delivery. It must not be swallowed or applied as a topical acne product. Confusing Cleocin oral and vaginal brand families could result in the wrong route, wrong ingredients in the vehicle and incorrect instructions.
A U.S. pharmacy label should state the route clearly. The oral clindamycin section discusses capsules and oral liquids separately.
Before filling, confirm that the pharmacy entry says Cleocin Vaginal Ovules and identifies 100 mg vaginal suppositories rather than cream or another brand. Pharmacy package images are helpful only as references; the actual product and labeling should be checked.
Ask how the supplied ovules are packaged, how the pharmacist will label directions and whether the clinician wrote any brand-specific restrictions. If a different vaginal form is offered, request clarification before accepting it.
The U.S. label for Cleocin Vaginal Ovules identifies them as a three-day treatment of bacterial vaginosis in non-pregnant women; it also states that adequate, well-controlled studies in pregnant women are lacking. This product-specific population detail should not be copied from the conventional vaginal cream label, which has different evidence and labeled context. The prescriber must assess pregnancy status, symptoms and whether the ovule form is appropriate.
The clindamycin for BV guide discusses the medical context and why an alternative such as metronidazole may be selected. This brand page does not choose a regimen for the individual reader.
The Cleocin Vaginal Ovules label states that its oleaginous suppository base can weaken latex or rubber condoms and vaginal diaphragms. It advises against use of those products within 72 hours after treatment. The patient should also read instructions about intercourse and other vaginal products during therapy.
The caution is formulation-specific. Clindesse cream has a different post-treatment interval, while Xaciato gel names polyurethane condoms specifically. Do not transfer one brand’s barrier guidance onto another product.
Cleocin Vaginal Ovules are contraindicated in patients with hypersensitivity to clindamycin, lincomycin or any suppository component, as well as those with a history of regional enteritis, ulcerative colitis or antibiotic-associated colitis. The ovule label warns that clindamycin can be absorbed systemically following vaginal administration and that antibiotic-associated diarrhea or colitis can be serious.
Seek prompt medical assessment for severe or persistent diarrhea, bloody stools, severe abdominal pain or signs of a serious allergic reaction during or following use. Vaginal side effects, including yeast-related symptoms, can occur. See the antibiotic-associated colitis guide for further warning-sign context without assuming every vaginal product has the same systemic exposure.
The fact that a product is described as “clindamycin vaginal” does not establish it is the Cleocin ovule brand. Generic product options depend on the precise dosage form and applicable regulatory status. The pharmacy can clarify what substitute, if any, is suitable for the prescription.
For products marketed under other vaginal brand names, see Clindesse cream and Xaciato gel; both are different formulation types, not generic Cleocin ovules.
U.S. Cleocin Vaginal Ovules are prescription-only. A licensed pharmacy should validate a clinician order and provide access to a pharmacist who can answer questions about route, packaging and safety.
If ordering remotely, use pharmacy verification guidance. The existence of an archived or current label must never be read as a current-stock promise.
Vaginal ovules may be billed differently from a tube of cream or a single-use vaginal gel because the product, quantity and coverage category differ. Brand-versus-generic choices and formulary status also influence what a patient pays.
Ask for a real patient-specific quote based on the prescribed ovule product. Our vaginal clindamycin pricing guide discusses these differences without inventing dollar figures.
Is this the Cleocin 100 mg vaginal ovule formulation? How many suppositories are included? Are directions printed for intravaginal use, and are the storage and barrier-product cautions available with this package? Those questions are more useful than asking merely for “Cleocin.”
The pharmacist should also explain what to do if the prescribed brand is not stocked, including whether the prescriber must approve any product change. Ask about potential side effects before leaving.
Do not confuse a clindamycin vaginal ovule with a topical antibiotic pad, a rectal suppository or Cleocin vaginal cream. The drug route is an essential part of the prescription, not a minor packaging detail.
For the broader acquisition pathway across all vaginal forms, see the vaginal clindamycin purchase guide. This brand page intentionally remains about the Cleocin 100 mg ovule product.
The branded vaginal suppositories are labeled at 100 mg clindamycin per ovule.
No. They are different vaginal formulations with different labels and dispensing units.
No. It is a vaginal suppository, not an oral capsule.
Yes. They are prescription-only.
Their oily base may weaken latex or rubber products; the label advises against those products within 72 hours after treatment.
No. Clindesse is a different single-dose vaginal cream product.
Availability must be confirmed directly with a pharmacy; a drug label alone does not establish stock.
Only when a clinician and pharmacist confirm an appropriate prescription change.
The labeled indication is bacterial vaginosis in non-pregnant women, and the label states that adequate well-controlled studies in pregnant women are lacking. Pregnancy concerns require individualized clinician evaluation.